Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Jul 10;138(2):141-149.
doi: 10.1161/CIRCULATIONAHA.118.034645. Epub 2018 May 1.

Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy

Aruna D Pradhan  1   2 , Aaron W Aday  2   3 , Lynda M Rose  2 , Paul M Ridker  2   3
Affiliations
Randomized Controlled Trial

Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy

Aruna D Pradhan et al. Circulation. .

Abstract

Background: The combination of statin therapy and PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition markedly lowers low-density lipoprotein cholesterol (LDL-C) and reduces cardiovascular event rates. Whether residual inflammatory risk as measured by on-treatment high sensitivity C-reactive protein (hsCRP) remains an important clinical issue in such patients is uncertain.

Methods: We evaluated residual inflammatory risk among 9738 patients participating in the SPIRE-1 and SPIRE-2 cardiovascular outcomes trials (Studies of PCSK9 Inhibition and the Reduction in Vascular Events), who were receiving both statin therapy and bococizumab, according to on-treatment levels of hsCRP (hsCRPOT) and LDL-COT measured 14 weeks after drug initiation. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death.

Results: At 14 weeks, the mean percentage change in LDL-C among statin-treated patients who additionally received bococizumab was -60.5% (95% confidence interval [CI], -61.2 to -59.8; P<0.001; median change, -65.4%) as compared to 6.6% (95% CI, -1.0 to 14.1; P=0.09; median change, 0.0%) for hsCRP. Incidence rates for future cardiovascular events for patients treated with both statin therapy and bococizumab according to hsCRPOT <1, 1 to 3, and >3 mg/L were 1.96, 2.50, and 3.59 events per 100 person-years, respectively, corresponding to multivariable adjusted hazard ratios of 1.0, 1.16 (95% CI, 0.81-1.66), and 1.62 (95% CI, 1.14-2.30) (P-trend=0.001) after adjustment for traditional cardiovascular risk factors and LDL-COT. Comparable adjusted hazard ratios for LDL-COT (<30, 30-50, >50 mg/dL) were 1.0, 0.87, and 1.21, respectively (P-trend=0.16). Relative risk reductions with bococizumab were similar across hsCRPOT groups (P-interaction=0.87).

Conclusions: In this post hoc analysis of the SPIRE trials of bococizumab in a stable outpatient population, evidence of residual inflammatory risk persisted among patients treated with both statin therapy and proprotein convertase subtilisin-kexin type 9 inhibition.

Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01975376, NCT01975389.

Keywords: LDL-C; PCSK9; PCSK9 inhibitor; hsCRP; inflammation; residual risk.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Mean percent change in lipid levels from baseline to 14 weeks according to hsCRPOT.
Median on-treatment lipid values in each hsCRPOT group are shown to the right of each plot.
Figure 2.
Figure 2.. Relationship between hsCRPOT on a continuous scale and the adjusted event rate for the trial primary endpoint (myocardial infarction, stroke, unstable angina requiring urgent coronary revascularization, and cardiovascular death).
Model adjusts for age, sex, current smoking, diabetes, hypertension, and body-mass index) statin intensity at enrollment (moderate-intensity or high-intensity), and LDL-COT. Dots represent individual hsCRPOT values. The solid red line indicates the estimated event curve from adjusted models.
Figure 3.
Figure 3.. Risk association of hsCRPOT and LDL-COT with incident cardiovascular events according to categories of each biomarker.
Adjusted for age, sex, current smoking, diabetes, hypertension, and body-mass index) statin intensity at enrollment (moderate-intensity or high-intensity), and hsCRPOT and LDL-COT as appropriate. Models for hsCRPOT are on the left and models for LDL-COT is on the right.
See this image and copyright information in PMC

Comment in

References

    1. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC and Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839–844. - PubMed
    1. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr . and Air Force/Texas Coronary Atherosclerosis Prevention Study I. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–1965. - PubMed
    1. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P and Reversal of Atherosclerosis with Aggressive Lipid Lowering I. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29–38. - PubMed
    1. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, Pravastatin or Atorvastatin E and Infection Therapy-Thrombolysis in Myocardial Infarction I. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28. - PubMed
    1. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM and Braunwald E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114:281–288. - PubMed

Publication types

MeSH terms

Associated data